Digital Therapeutics Market

Overview

The global Digital Therapeutics Market was valued at USD 9.3 billion in 2025 and is projected to reach USD 48.0 billion by 2034, growing at a CAGR of 20.0% during the forecast period (2026–2034). The market is driven by the rising burden of chronic disease, wider clinician acceptance of software-based treatment, and the steady creation of reimbursement pathways that let regulated digital treatments be prescribed and paid for like other medical interventions. The market is shifting from conventional, standalone, single-condition mobile applications toward connected, multi-condition care platforms that combine software, sensors, coaching, and prescribing in one workflow. Developers are pairing digital treatment with drug therapy, including weight management programs built around anti-obesity medicines, and they use artificial intelligence to personalize content and track engagement. Government initiatives such as the payment codes for digital mental health treatment devices under the U.S. Medicare program, which were extended to devices for attention-deficit hyperactivity disorder in the 2026 Medicare Physician Fee Schedule, are widening reimbursement in the United States. The Access to Prescription Digital Therapeutics Act, introduced in the U.S. Congress in 2025, proposes a dedicated Medicare benefit category for prescribed software treatments. By Region, North America held the largest share of the market in 2025, supported by early regulatory clearances, expanding payer coverage, and a large base of employer-sponsored digital care programs. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by rising smartphone use, a growing chronic disease burden, and new regulatory pathways for software medical devices across Japan, South Korea, China, and India.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Connected Multi-Condition Platforms and AI-Guided Personalization Emerging as a Transformational Trend

• Developers are moving from single-condition applications to platforms that cover diabetes, hypertension, weight, sleep, and behavioral health within one member experience. This reduces the number of vendors that health plans and employers must manage. Buyers also gain a single data view of each member, which helps them track outcomes across overlapping chronic conditions.
• Artificial intelligence now adjusts lesson order, reminder timing, and coaching prompts based on how each patient behaves inside the application. Machine learning models flag members who are losing interest so care teams can step in early. These tools raise program completion, which is the main clinical factor linked to digital therapeutic outcomes.
• Drug makers are pairing digital treatment with prescription medicines to improve adherence and to differentiate branded therapies. Combination programs for obesity, oncology, immunology, and mental health are appearing in partnership deals. This turns digital treatment from a stand-alone product into a companion offering that pharmaceutical sales teams and payers can support at scale.
• The U.S. Food and Drug Administration announced the TEMPO pilot, alongside the CMS ACCESS model, whose first cohort began in July 2026. The FDA has since selected Dexcom as the first TEMPO participant. The pilot lets chosen digital health devices serve ACCESS participants while manufacturers collect real-world data to support later marketing authorization.

KEY MARKET DRIVER

Rising Chronic Disease Burden and Expanding Reimbursement Coverage is the Key Driver

• Diabetes, obesity, hypertension, and mental health conditions are raising treatment demand faster than clinics can add staff. Digital treatment programs give health systems a way to extend care between visits without adding appointment capacity. Clinicians can prescribe structured, monitored programs that patients complete at home, which improves access in rural and underserved areas.
• Payers are shifting from paying only for drugs and procedures toward paying for software that produces measurable outcomes. Outcome-linked contracts reduce the financial risk of trying a new product. As more insurers publish coverage policies for prescribed digital treatments, physician offices gain the confidence to include them in routine care plans.
• Growing clinical evidence is strengthening physician trust. Randomized controlled trials now support digital treatment for insomnia, depression, anxiety, migraine, and substance use disorders. Clinical practice guidelines already recommend cognitive behavioral therapy as first-line care for several of these conditions, so software that delivers the same therapy fits directly into existing treatment pathways.
• Germany's Federal Institute for Drugs and Medical Devices (BfArM) reported 251 applications to its DiGA fast-track procedure as of July 15, 2026, with 60 positive decisions. Around 73 million people covered by statutory health insurance are entitled to use a prescribed DiGA. The directory shows how a national reimbursement route turns regulatory approval into real patient access.

KEY MARKET OPPORTUNITY

Expansion of Companion Programs for Obesity Medicines and Neurology Creates Significant Market Opportunity

• Anti-obesity medicines are creating a large group of patients who need structured support on nutrition, muscle preservation, and long-term habit change. Digital programs paired with these prescriptions can improve persistence on treatment. This gives developers a clear clinical role, and it gives payers a way to protect the value of expensive drug spending.
• Neurology and psychiatry remain lightly served by digital options. Attention deficit, psychosis, chronic pain, and cognitive decline have few non-drug choices, and pipeline products continue to enter pivotal studies. New approvals would open additional prescriber groups, such as neurologists and psychiatrists, who have had very few software-based tools to date.
• Emerging economies represent a largely untapped customer base. Rising smartphone use and public digital health infrastructure in India, Brazil, and Saudi Arabia support remote delivery of chronic care. Local language content and low-cost distribution through public health systems can reach large populations that lack easy access to trained specialists and long-term care.
• Omada Health announced that it will serve as an independent program administrator in Eli Lilly's Employer Connect program. Omada will offer its GLP-1 Care Track, covering clinical evaluation, prescribing, and medication management, directly to employers. The move adds a direct-to-employer channel beside its pharmacy benefit manager and cash-pay pathways.

Digital Therapeutics Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Application

Diabetes held the largest market share in 2025 because the condition requires daily self-management, which software handles well. Digital programs combine glucose tracking, dietary guidance, medication reminders, and coaching, helping patients improve glycemic control between clinic visits. Established guidelines that support structured self-management education, a large global patient base, and earlier product approvals than other conditions keep diabetes ahead of other applications. Health plans and employers also favor diabetes programs because lower blood sugar levels translate into measurable savings on complications, emergency visits, and hospital use across large member groups.

Central Nervous System Disorders are projected to grow at the fastest CAGR during the forecast period. Regulators have now cleared prescription software for depression, generalized anxiety, insomnia, migraine, and attention-deficit hyperactivity disorder, which shows that digital treatment can meet clinical standards in neurological and mental health care. Shortages of psychiatrists and therapists create long waiting times, so scalable digital cognitive behavioral therapy meets a real access gap. Wider payer coverage for prescribed mental health software and a growing pipeline for schizophrenia and cognitive conditions are expected to widen prescribing and speed adoption.

Application categories include

• Diabetes (Dominating Segment)
• Obesity
• Central Nervous System Disorders (Highest CAGR Segment)
• Cardiovascular Diseases
• Respiratory Diseases
• Others

Analysis by Component

Software held the largest market share in 2025 because the core therapeutic intervention in most products is delivered through applications and web platforms. Software scales at low marginal cost, can be updated remotely, and runs on devices that patients already own, which removes hardware barriers to adoption. Regulators treat treatment software as a medical device, so validated products carry clear clinical claims that clinicians and payers can assess. Frequent content updates, integration with electronic health records, and the ability to add new conditions on one platform strengthen the position of the software component.

Services are projected to grow at the fastest CAGR during the forecast period. Buyers increasingly want programs that include human coaching, clinical oversight, onboarding, remote monitoring, and data reporting alongside the software. Outcome-based contracts reward vendors that keep patients engaged, and engagement usually improves when trained coaches and care teams support the application. Growth in prescribing platforms, telehealth links, and medication management services around digital programs adds recurring service revenue. Health systems that lack in-house digital expertise also outsource implementation and patient support, which expands demand for managed service offerings.

Component categories include

• Software (Dominating Segment)
• Hardware
• Services (Highest CAGR Segment)

Analysis by Sales Channel

Over-the-Counter held the largest market share in 2025 because most programs reach users through employers, health plans, and direct-to-consumer subscriptions that do not require an individual prescription. Enrollment is quick, which supports large user volumes, and sponsors can offer programs to entire member populations rather than only diagnosed patients. Products focused on lifestyle change, weight, blood sugar, sleep, and stress management fit this route well. Low friction at signup, familiar app store distribution, and strong employer interest in controlling chronic disease costs keep this channel ahead of prescribed products. Subscription pricing also lets sponsors scale enrollment without waiting for individual clinical visits.

Prescription-Based is projected to grow at the fastest CAGR during the forecast period. Regulators have created clearer pathways for software that carries defined clinical claims, and payers are building coverage and billing rules that reimburse prescribed digital treatments. Physicians trust products backed by randomized trials and formal clearance, which supports wider ordering by psychiatrists, neurologists, sleep specialists, and primary care teams. Electronic prescribing links and pharmacy-style code delivery are removing the workflow barriers that limited early prescription volumes, and each new indication keeps widening the eligible patient pool for prescribing clinicians and the pharmacies that dispense access codes.

Sales Channel categories include

• Over-the-Counter (Dominating Segment)
• Prescription-Based (Highest CAGR Segment)

Analysis by End User

Patients held the largest market share in 2025 because they are the direct users of every digital therapeutic product and the point where engagement, adherence, and outcomes are measured. A large share of programs is accessed directly by individuals through app stores, employer benefits, and health plan portals, which makes the patient the primary channel for enrollment. Growing health literacy, wider smartphone ownership, and a preference for private, home-based care support demand. Chronic conditions require months of continuous use, which produces sustained activity and repeat engagement from this group. Patient reviews, peer communities, and visible progress tracking further encourage continued participation.

Healthcare Providers are projected to grow at the fastest CAGR during the forecast period. Hospitals, specialty clinics, and physician practices are starting to prescribe digital treatment as part of routine care plans and to bill for patient management time where reimbursement rules allow. Integration with electronic health records, simple ordering portals, and clinician dashboards reduces the extra workload of adopting a new tool. Workforce shortages in mental health, sleep medicine, and chronic disease management push providers toward scalable digital options that extend clinician reach and support patients between appointments, particularly for follow-up care after discharge.

End User categories include

• Patients (Dominating Segment)
• Healthcare Providers (Highest CAGR Segment)
• Payers
• Employers

By Region

North America held the largest market share in 2025, accounting for about 40% of the global market. The United States leads through early FDA clearances for prescription software, expanding Medicare and commercial payer coverage, and a large base of employer-sponsored digital care programs. FDA regulations that classify digital therapy devices for conditions such as amblyopia and attention-deficit hyperactivity disorder give developers defined regulatory routes. Canada offers a growing base of provincial virtual care programs that can host digital treatment, while Mexico's large diabetes population supports early demand for remote chronic care. Competition is intense, with digital-first specialists, pharmaceutical partners, and health plans all building or buying programs.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period. Japan leads the region, with regulatory approval and national insurance coverage for prescription treatment apps, including products for hypertension and nicotine dependence. South Korea's Ministry of Food and Drug Safety has approved locally developed digital therapeutic devices for insomnia, giving the country a defined approval route. China combines a very large population with diabetes and mental health needs and a deep domestic medical software sector, while India offers a fast-growing smartphone base and the Ayushman Bharat Digital Mission infrastructure that can carry remote care. Limited access to specialists across Rest of Asia-Pacific adds further demand.

Countries and Regions Covered

North America (Dominating Region)

• United States (Largest Country Market)
• Canada
• Mexico

Asia-Pacific (Fastest Growing Region)

• China
• India (Fastest-Growing Country Market)
• Japan (Largest Country Market)
• South Korea
• Rest of Asia-Pacific

Europe

• Germany (Largest Country Market)
• France
• United Kingdom
• Italy
• Rest of Europe

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin America

Middle East & Africa

• Saudi Arabia (Largest Country Market)
• United Arab Emirates (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The Digital Therapeutics Market is fragmented, with digital-first specialists, chronic care platforms, and pharmaceutical partners competing across conditions and geographies. No single company holds a dominant global share because clinical claims, reimbursement routes, and regulatory approvals differ by country and by indication. Leading companies such as Click Therapeutics, Omada Health, Big Health, DarioHealth, and Welldoc compete on clinical evidence, payer contracts, and platform breadth. Key success factors include randomized trial data, regulatory clearance, integration with clinical workflows, and proven outcome-based pricing. Strategic priorities center on multi-condition platforms, companion programs for prescription drugs, and entry into reimbursed markets such as Germany and Japan. Partnership and acquisition activity is rising as larger platforms buy smaller developers to add regulated products and reimbursement access.

Key Players

• Click Therapeutics, Inc. (US)
• Omada Health, Inc. (US)
• Big Health, Inc. (US)
• DarioHealth Corp. (US)
• Welldoc, Inc. (US)
• Hinge Health, Inc. (US)
• Sword Health, Inc. (US)
• Sidekick Health (Iceland)
• Oviva AG (Switzerland)
• HelloBetter (Germany)
• Selfapy GmbH (Germany)
• CureApp, Inc. (Japan)
• Luminopia, Inc. (US)
• Freespira, Inc. (US)
• Lumos Labs, Inc. (US)

Recent Market Developments

• In January 2026, Sword Health acquired Kaia Health in a deal valued at USD 285 million, adding Kaia's musculoskeletal and pulmonary digital therapy programs and its position in Germany's DiGA reimbursement pathway. The transaction shows consolidation among digital therapy providers and gives a U.S. company direct entry into Germany's reimbursed market.
• In February 2026, Big Health raised USD 23.7 million to expand adoption of SleepioRx and DaylightRx through health systems and telemedicine providers. The funding supports commercial rollout of two FDA-cleared digital treatments for insomnia disorder and generalized anxiety disorder in the United States.
• In February 2026, Freespira launched Freespira Sensor Technology v5, its fifth-generation device that combines the sensor and display into a single unit for at-home treatment of panic disorder and post-traumatic stress disorder. The simpler hardware design supports wider distribution through health plans, self-insured employers, and the Veterans Administration.
• In April 2026, Boehringer Ingelheim invested USD 50 million in Click Therapeutics' Series D and transferred full commercial and marketing rights for CT-155, an investigational prescription digital therapeutic for negative symptoms of schizophrenia, to Click. The restructured agreement places a product that met its primary endpoint in a Phase III study on a path to launch after FDA clearance.

Frequently Asked Questions